Abstract
Background and Objective: Large-scale phase III clinical trials have established immunotherapy as a standard of care for advanced esophageal squamous cell cancer (ESCC). However, the optimal timing—whether to use it in the first-line or second-line setting—remains debated. This study investigates whether early immunotherapy (EIT) improves long-term survival compared to late immunotherapy (LIT).
Methods: This retrospective study analyzed 359 patients with locally advanced or metastatic ESCC. Patients were divided into EIT (first-line) and LIT (second-line) groups. Propensity score matching (PSM) was used to balance baseline characteristics.
Results: After matching, 107 patients remained in each group. While EIT significantly improved progression-free survival (PFS1: 8.7 vs. 7.6 months, $P=0.032$; PFS2: 12.97 vs. 12.93 months, $P=0.045$), it did not significantly improve overall survival (OS: 15.7 vs. 17.7 months, $P=0.185$). Multivariate analysis identified EIT and tumor differentiation as independent predictors of OS.
Conclusions: For advanced ESCC, early immunotherapy improves progression-free survival but does not translate into a significant overall survival benefit compared to sequential use.
Introduction
Esophageal squamous cell cancer (ESCC) is a highly aggressive malignancy, particularly prevalent in China. While immunotherapy has revolutionized treatment, clinicians face a strategic dilemma: should these agents be deployed immediately in the first-line setting (Early Immunotherapy, EIT), or reserved for when initial chemotherapy fails (Late Immunotherapy, LIT)? Theoretically, early intervention might prevent tumor complexity, but real-world data on the long-term survival benefits of this "earlier is better" approach versus a sequential strategy are limited.
Methods
The researchers conducted a retrospective analysis of 359 patients treated at Shandong Cancer Hospital between 2018 and 2021. To ensure a fair comparison, the study utilized Propensity Score Matching (PSM) at a 1:1 ratio to balance baseline characteristics such as age, sex, and tumor location.
Patients were categorized into:
- EIT Group: Received immunotherapy as part of first-line treatment.
- LIT Group: Received standard chemotherapy first, followed by immunotherapy as second-line treatment.
Key Results
Survival Outcomes
The study revealed a disconnect between progression-free survival and overall survival:
- Progression-Free Survival (PFS): EIT showed a clear advantage. PFS1 was 8.7 months for EIT vs. 7.6 months for LIT ($P=0.032$). PFS2 also favored EIT at 12.97 months vs. 12.93 months ($P=0.045$).
- Overall Survival (OS): There was no statistically significant difference. The EIT group had a median OS of 15.7 months compared to 17.7 months in the LIT group ($P=0.185$).
Multivariate Analysis
Despite the lack of OS difference in the matched cohort, COX multivariate analysis indicated that the treatment group (EIT vs. LIT) and the degree of tumor differentiation were significant independent factors affecting overall survival.
Key Insights and Discussion
- The "Catch-up" Effect: The lack of OS benefit in the EIT group may be attributed to subsequent treatment opportunities. Approximately 30% of the LIT group received third-line therapy, compared to only 15.5% of the EIT group, potentially equalizing survival outcomes.
- Subgroup Benefits: Early immunotherapy appeared more beneficial for specific subgroups: males, patients under 65, those with middle thoracic tumors, and those receiving a paclitaxel plus platinum (TP) chemotherapy backbone.
- Safety Profile: Treatment-related adverse events (TRAEs) were similar across both groups, with roughly 60% of patients experiencing Grade 3 or higher side effects, suggesting that early use does not significantly increase the toxicity burden.
Limitations and Future Work
As a retrospective study, these findings are subject to inherent biases. The lack of PD-L1 expression data—a critical biomarker for immunotherapy response—limits the ability to assess if biological profiles influenced the outcomes. Future prospective, randomized trials incorporating PD-L1 status are necessary to definitively determine the optimal timing for immunotherapy in ESCC.
Summary updated